

The All-Rounder

By Stephanie Kappes, Alfred Steinbach and Katinka Ruth at Metrohm

Ion chromatography is a flexible technique with a wide variety of practical uses in the pharma sector – here we take a look at some pertinent trends and recent advances in its application

High standards have to be met by the pharmaceutical industry when it comes to drug quality and safety. These standards are documented in pharmacopoeias as officially recognised pharmaceutical rules, and published as legal tools of customer protection by authorities such as governments and medical societies. The identification of a drug depends on sensitive, reliable instruments and methods – as does the determination of the drug's compliance with applicable regulations.

Ion chromatography (IC) is the method of choice to determine active ingredients, excipients and traces of impurities, as well as metabolites in the form of organic and inorganic ions or polar substances, in a number of pharmaceuticals, pharmaceutical solutions, and even body fluids. It can determine the presence of several substances within a very short time in a single analysis – and even distinguish chemically similar analytes. The concentration of analytes can vary from ng/L up to the per cent range. The large selection of separation columns and elution systems available makes IC useful for almost any kind of analyte. Interfering effects caused by the sample matrix can easily be avoided

by using the right sample preparation or choosing a suitable detection method. Inline sample preparation is a feature of many modern IC systems,

as the focus of recent advances in IC has been mainly on ease of use. However, convenience is not the only advantage brought by the automation of the IC process: reducing human interference to a minimum also means reducing the chances of mistakes and contamination.

Depending on the requirements of analyte and matrix, there is a broad range of detection methods to choose from:

- Conductivity detection with and without suppression
- Electrochemical detection
- Spectrophotometric detection with and without post-column derivatisation (ultraviolet-visible spectrophotometry)
- Coupled detection methods such as IC-mass spectrometry (MS) and IC-inductively coupled plasma-MS

Pharmaceutical samples come in many different forms which require different ion chromatographic approaches. What follows is an overview of frequent sample types with relevant example analyses.

Pharmaceutical Solutions

The term 'pharmaceutical solutions' denotes isotonic, haemodialysis, or infusion solutions. They contain anions, cations, carbohydrates and organic acids, the concentrations of which frequently differ from one another by several orders of magnitude. Within the context of production monitoring and final

quality control, an analysis method is required that can determine these ingredients with a high degree of precision. In addition, the analysis should be quick and require minimal effort. With its intelligent analytical procedure and automatic inline sample preparation, IC fully accomplishes this task.

Two example analyses of haemodialysis solutions are shown in Figures 1-2. Patients suffering from renal failure require haemodialysis to compensate for the loss of the kidney's blood-cleansing function. During the process, the patient's blood exchanges solutes with a haemodialysis solution through a semi-permeable membrane. The exchanged solutes include, among others, waste products such as urea and phosphate, which diffuse out of the blood and into the dialysis solution along the concentration gradient. The composition of dialysis solutions is complex, because the removal of solutes from the blood changes its osmotic activity; therefore, it has to take place at a controlled rate, which is achieved by the right solute concentration. A strong change in osmotic activity can cause dialysis disequilibrium syndrome where, due to the low solute concentration in blood, solutes are washed out from other body compartments.

Figure 1 shows the simultaneous determination of citrate and

Keywords

Ion chromatography

Quality control

Pharmaceutical solutions

acetate in diluted haemodialysis solution. In part A, an anion standard was measured; part B shows the sample determination. Citrate is added to haemodialysis solutions for its anticoagulant properties and acetate is added as a buffer substance. It is transferred to the patient's bloodstream during haemodialysis and stabilises the blood's pH value. This is necessary because the kidneys of dialysis patients are not capable of excreting acid components – therefore, patients are often acidotic.

Besides citrate and acetate, the chromatogram reveals the presence of a close to physiological concentration of chloride. By using physiological solute concentrations, the concentration gradient is reduced to a minimum, and a dynamic equilibrium is reached between blood and dialysis solution. The loss of certain solutes – including chloride – is thereby prevented.

Figure 2 shows the determination of cations in haemodialysis concentrate after an automated inline dilution step. Like chloride, the cations are present in close to physiological concentrations to avoid their drainage from patients' blood by osmosis.

Active Pharmaceutical Ingredients

Active pharmaceutical ingredients (APIs) in medicines such as gentamicin, neomycin, cefadroxil, or bethanechol chloride can be determined by IC in accordance with the regulations of the US Pharmacopeia and the European Pharmacopoeia. The requirements regarding precision, separation and recovery of the analytes are described in detail in the pharmacopoeias. Figure 3 (see page 16) depicts the ion




Figure 1: IC measurement on a Metrosep A Supp 7 - 250/4.0 using Na_2CO_3 gradient elution, followed by sequential suppression and conductivity detection

A: Anion standard including acetate and citrate

B: Acetate and citrate in haemodialysis solution

Figure 2: Cations in diluted haemodialysis concentrate using the Metrosep C 4 - 150/4.0 column and non-suppressed conductivity detection

Figure 3: IC determination of the antibiotic gentamicin by pulsed amperometric detection; column: Polymer Laboratories RP-S; eluent: 60g/L Na₂SO₄, 1.75g/L sodium octane sulfonate, 1.34g/L NaH₂PO₄, 8mL/L THF (pH = 3, H₃PO₄); post-column addition: 300mmol/L NaOH





Figure 4: Irbesartan sample spiked with 5-80µg/L azide; column: Metrosep A Supp 10 - 250/4.0; eluent: 5mmol/L Na₂CO₃, 5mmol/L NaHCO₃; inline matrix elimination with 70:30 (v/v) methanol/water




chromatogram of an analysis of gentamicin, an antibiotic belonging to the group of aminoglycosides. Aminoglycosides are bactericidal antibiotics which block bacterial protein biosynthesis by binding to ribosomes, thereby causing mistakes in the translation from

messenger ribonucleic acid to DNA. Gentamicin consists of several closely related compounds, namely gentamicin C₁, gentamicin C_{1a}, and gentamicin C₂, C_{2a} and C_{2b}. In spite of their structural similarity, IC achieves a good separation of the different gentamicin components.

Impurities in Pharmaceuticals

Apart from API analysis, it is also possible to determine impurities in pharmaceutical products by IC. Even small concentrations of an impurity can cause significant side-effects. For example, in the synthesis of the antihypertensive irbesartan, azide can be detected in traces as an impurity in the product. Azide is strongly toxic to humans and its concentration in irbesartan is therefore subject to rigorous controls. The US Pharmacopeia recommends ion chromatographic azide determination after direct injection according to USP 621. In this method, a transfer solution consisting of the IC eluent and suitable organic solvent is used to remove the API from the analytical column. However, this procedure is tedious, time-consuming and cannot be automated.

Azide determination is more selective, more sensitive and, above all, quicker with the use of inline matrix elimination, where the interfering pharmaceutical matrix is separated from the target analyte in the course of sample preparation. The ion chromatogram shows the analysis of an irbesartan sample spiked with different concentrations of azide (see Figure 4). The signal is recorded by a conductivity detector following sequential suppression. Table 1 lists the average recovery values of azide that were achieved over three measurements, as well as



Apart from API analysis, it is also possible to determine impurities in pharmaceutical products by IC. Even small concentrations of an impurity can cause significant side-effects

the mean conductivity measured by the detector and the relative standard deviation.

The determination of azide in irbesartan with preceding matrix elimination fulfils all requirements of the regulatory authorities which concern the selectivity of the method, its limits of detection and quantitation, precision, linearity, accuracy and robustness. Thus, it can be used as a quicker and more sensitive alternative to the proposed determination according to USP 621.

Radio IC

Radio IC aims to determine the radiochemical purity of radiopharmaceuticals. These are radioactive substances which are used for medical purposes, mainly in diagnostics, but also in the treatment and prevention of certain diseases. [^{18}F]fluorodeoxyglucose and [^{18}F]fluorocholine are two prominent examples of radiotracers that are used in diagnostics by positron emission tomography (PET). They are labelled with the radionuclide [^{18}F]fluorine. During the radioactive decay of this unstable isotope, a proton in the nucleus of [^{18}F]fluorine changes to a neutron. This is accompanied by the emission of a neutrino and a positron. The latter combines with an electron in the surrounding tissue, resulting in annihilation of both particles and emission of two photons (gamma rays) in opposite directions, each with an energy of 0.511 MeV. From the data acquired through coincidence detection of the photon pair, the location of its emission in the patient's body is calculated. This location coincides closely with the location of the original radiotracer molecule, and

thus reveals information on its activity.

The purity of radiotracers is of crucial importance. The highly energetic gamma rays emitted during the combination of a positron with an electron are harmful to the human body. By using a pure radiotracer, thereby avoiding the injection of free [^{18}F]fluorine or other radioactive contaminants, the amount of radioactive substance administered to the patient can be kept to a minimum.

The quality control of radiotracers is established by radio IC in the short time between their synthesis and the recording of the three-dimensional PET scan. The separation step in radio IC is the same as in regular IC – apart from the fact that it happens behind lead doors. What really sets radio IC apart from conventional IC is the detection step, in which a radioactivity detector is added to the setup. The radioactivity chromatogram reveals the presence – or, ideally, the absence – of radioactive contaminants.

Conclusion

Today, IC covers a diverse field of applications in the pharma industry. A selection of three out of more than 80 applications is listed in Table 2. The technique has become an extremely versatile method due to the large number of different columns, eluent and gradient options, sample preparation techniques, and automation possibilities that are available to the user.

Table 1: Precision and recovery of azide

	Peak area		Recovery (%)
	Mean value ($\mu\text{S}/\text{cm}$)	Relative standard deviation (%)	
5 $\mu\text{g}/\text{L}$ spike	0.4223	1.96	101.71
30 $\mu\text{g}/\text{L}$ spike	2.5754	0.14	103.38
n=3 measurements			

Table 2: Selection of IC applications in the pharma industry

Pharmaceutical	Analyte		Detection
Adrenaline	Adrenaline	API	Amperometric detection
Ibuprofen	Ibuprofen, Valerophenone	API	Spectrophotometric detection
Zoledronate/ Zoledronic acid	Phosphite, phosphate	Impurities	Conductivity detection



Stephanie Kappes is Scientific Technical Writer in the Marketing Department of Metrohm, Switzerland. She earned her Bachelor's degree in Nanosciences from the University of Basel, Switzerland.

During her Master's studies of Molecular and Cellular Life Sciences, which she completed at Utrecht University, The Netherlands, in 2012, Stephanie focused on the public communication of science.
Email: ska@metrohm.com



Dr Alfred Steinbach is Scientific Technical Writer in the Marketing Department of Metrohm. He obtained his Master's degree in Nuclear Chemistry from the University of Cologne, Germany, and his PhD in Environmental and Analytical

Biogeochemistry from the University of Hamburg, Germany. Before obtaining his PhD and joining Metrohm in 2006, Alfred carried out research in nuclear, analytical and environmental chemistry and worked as Production Manager at BASF Venezolana SA in South America.
Email: ast@metrohm.com



Dr Katinka Ruth is Product Specialist in the Competence Centre for Ion Chromatography at Metrohm. She studied Chemistry at the Technical University of Munich, Germany, where she obtained her Master's qualification

with majors in Organic Chemistry and Biotechnology. Katinka's PhD was conducted at the Swiss Federal Institute of Technology and the Swiss Federal Laboratories for Materials Science and Technology. Before joining Metrohm, she worked as Scientific Assistant at the Swiss Federal Institute of Aquatic Science and Technology.
Email: kru@metrohm.com